Search Results

At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique ‘off-the-shelf allogeneic matrix product to cure common but challenging orthopedic conditions, has potential to replace existing allogeneic bone substitutes to heal fractures

Novadip Biosciences SA announced that the first US patient has been implanted with its investigational tissue regeneration product, NVD-003, in its Phase 1b/2a clinical trial in Congenital Pseudarthrosis of Tibia, a rare pediatric bone condition.

Novadip Biosciences SA announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company.

Novadip Biosciences announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding.

Novadip Biosciences SA today announced that the first patient has been implanted with its investigational tissue regeneration product, NVD-003, in its Phase 1b/2a clinical trial treating four patients with Congenital Pseudarthrosis of Tibia (CPT).

Novadip Biosciences SA announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003, in patients with severe bone non-union of the lower limb following trauma.

Novadip Biosciences today announced that it has raised €19 million in the first close of a Series B financing

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.